Distribution of data and unique material resources made with NIH funding

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Distribution of data and unique material resources made with NIH funding

ABSTRACT: The research community, particularly in academic and public sector institutions, recognises that scientists have an obligation to publish the results of their research and otherwise make available data or unique materials that are necessary for others to replicate or advance their research. Over the past 15 years, the US National Institutes of Health (NIH) has developed policies to make such obligations a requirement for recipients of NIH funding...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

Management
Policy
Finance
Law
Regulation
Bioethics

For more information, see the Journal of Commercial Biotechnology website

1 Likes

/1 Tweets/in General Biotechnology

September 23, 2013

23 Sep 2013

Commercial biotechnology in Latin America: Current opportunities and challenges

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Commercial biotechnology in Latin America: Current opportunities and challenges

Go to paper

ABSTRACT: The unparalleled growth of commercial biotechnology in the USA and Europe during the past two decades has also been marked by its steady development in Latin America. Brazil, Cuba, Argentina, Chile, Mexico and others have made significant strides in building their research and production capacity in modern biotechnology...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

Management
Policy
Finance
Law
Regulation
Bioethics

For more information, see the Journal of Commercial Biotechnology website

1 Likes

/2 Tweets/in General Biotechnology

September 23, 2013

23 Sep 2013

Who are the most successful drug patent challengers?

This chart shows the companies with the successful drug patent challenges from last year.

The most successful drug patent challengers in 2012 were Mylan Pharms Inc, Lupin Pharms, Ivax Sub Teva Pharms, Teva Pharms, Perrigo Israel, Teva, Watson Labs Inc Fl, Dr Reddys Labs Ltd, Innopharma Inc, and Mylan Labs.

For more infographics, see the DrugPatentWatch Pharmaceutical Innovation Infographics.

Do you have a response to this infographic? Respond in the comments section below.

0 Comments/

1 Likes

/3 Tweets/in General Biotechnology

September 11, 2013

11 Sep 2013

Drug Patent Expirations in September 2013

Drug Patent Expirations for September 2013

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
LUPRON DEPOT	Abbvie Endocrine Inc	leuprolide acetate	5,575,987	Sep 2, 2013
LUPRON DEPOT-PED	Abbott Endocrine	leuprolide acetate	5,575,987	Sep 2, 2013
LUPRON DEPOT	Abbott Endocrine	leuprolide acetate	5,716,640	Sep 2, 2013
LUPRON DEPOT	Abbvie Endocrine Inc	leuprolide acetate	5,716,640	Sep 2, 2013
LUPRON DEPOT-PED	Abbott Endocrine	leuprolide acetate	5,716,640	Sep 2, 2013
LUPRON DEPOT	Abbott Endocrine	leuprolide acetate	5,575,987	Sep 2, 2013
SYMLIN	Amylin Pharms Llc	pramlintide acetate	6,608,029	Sep 7, 2013
OPANA ER	Endo Pharms	oxymorphone hydrochloride	5,662,933	Sep 9, 2013
OPANA ER	Endo Pharms	oxymorphone hydrochloride	5,958,456	Sep 9, 2013
MYRBETRIQ	Apgdi	mirabegron	6,699,503	Sep 10, 2013
PRELAY	Sankyo	troglitazone	6,046,202	Sep 15, 2013
CELLCEPT	Roche Palo	mycophenolate mofetil hydrochloride	5,543,408	Sep 15, 2013
REZULIN	Pfizer Pharms	troglitazone	5,602,133	Sep 15, 2013
CRINONE	Watson Labs	progesterone	5,543,150	Sep 15, 2013
PRELAY	Sankyo	troglitazone	5,602,133	Sep 15, 2013
REZULIN	Pfizer Pharms	troglitazone	6,046,202	Sep 15, 2013
CANCIDAS	Merck	caspofungin acetate	5,792,746*PED	Sep 16, 2013
CANCIDAS	Merck	caspofungin acetate	5,378,804*PED	Sep 16, 2013
AVODART	Glaxosmithkline	dutasteride	5,846,976	Sep 17, 2013
JALYN	Glaxosmithkline	dutasteride; tamsulosin hydrochloride	5,846,976	Sep 17, 2013
DIASTAT ACUDIAL	Valeant	diazepam	5,462,740	Sep 17, 2013
AVODART	Glaxosmithkline	dutasteride	5,998,427	Sep 17, 2013
JALYN	Glaxosmithkline	dutasteride; tamsulosin hydrochloride	5,998,427	Sep 17, 2013
DIASTAT	Valeant	diazepam	5,462,740	Sep 17, 2013
NIASPAN	Abbvie	niacin	6,406,715	Sep 20, 2013
ADVICOR	Abbvie	lovastatin; niacin	6,746,691	Sep 20, 2013
SIMCOR	Abbvie	niacin; simvastatin	6,676,967	Sep 20, 2013
NIASPAN	Abbvie	niacin	7,998,506	Sep 20, 2013
ADVICOR	Abbvie	lovastatin; niacin	6,818,229	Sep 20, 2013
SIMCOR	Abbvie	niacin; simvastatin	6,818,229	Sep 20, 2013
NIASPAN	Abbvie	niacin	6,746,691	Sep 20, 2013
SIMCOR	Abbvie	niacin; simvastatin	7,998,506	Sep 20, 2013
ADVICOR	Abbvie	lovastatin; niacin	6,406,715	Sep 20, 2013
NIASPAN TITRATION STARTER PACK	Abbvie	niacin	6,129,930	Sep 20, 2013
NIASPAN	Abbvie	niacin	6,676,967	Sep 20, 2013
SIMCOR	Abbvie	niacin; simvastatin	6,406,715	Sep 20, 2013
ADVICOR	Abbvie	lovastatin; niacin	7,998,506	Sep 20, 2013
NIASPAN TITRATION STARTER PACK	Abbvie	niacin	6,746,691	Sep 20, 2013
NIASPAN	Abbvie	niacin	7,011,848	Sep 20, 2013
ADVICOR	Abbvie	lovastatin; niacin	6,676,967	Sep 20, 2013
SIMCOR	Abbvie	niacin; simvastatin	6,746,691	Sep 20, 2013
NIASPAN	Abbvie	niacin	6,818,229	Sep 20, 2013
SIMCOR	Abbvie	niacin; simvastatin	7,011,848	Sep 20, 2013
ADVICOR	Abbvie	lovastatin; niacin	6,129,930	Sep 20, 2013
NIASPAN TITRATION STARTER PACK	Abbvie	niacin	7,011,848	Sep 20, 2013
NIASPAN	Abbvie	niacin	6,129,930	Sep 20, 2013
SIMCOR	Abbvie	niacin; simvastatin	6,129,930	Sep 20, 2013
ADVICOR	Abbvie	lovastatin; niacin	7,011,848	Sep 20, 2013
NIASPAN TITRATION STARTER PACK	Abbvie	niacin	6,406,715	Sep 20, 2013
ZYFLO CR	Cornerstone Therap	zileuton	6,183,778	Sep 21, 2013
NOVOLOG MIX 70/30 FLEXPEN	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,834,422	Sep 28, 2013
NOVOLOG MIX 50/50	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,840,680	Sep 28, 2013
NOVOLOG MIX 70/30 PENFILL	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,834,422	Sep 28, 2013
NOVOLOG MIX 50/50	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,834,422	Sep 28, 2013
ELIGARD	Tolmar Therap	leuprolide acetate	6,395,293	Sep 28, 2013
NOVOLOG MIX 70/30 PENFILL	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,547,930	Sep 28, 2013
NOVOLOG MIX 70/30	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,840,680	Sep 28, 2013
NOVOLOG MIX 70/30 FLEXPEN	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,547,930	Sep 28, 2013
NOVOLOG MIX 70/30 FLEXPEN	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,840,680	Sep 28, 2013
NOVOLOG MIX 50/50	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,547,930	Sep 28, 2013
NOVOLOG MIX 70/30 PENFILL	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,840,680	Sep 28, 2013
NOVOLOG MIX 70/30	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,547,930	Sep 28, 2013
NOVOLOG MIX 70/30	Novo Nordisk Inc	insulin aspart protamine recombinant; insulin aspart recombinant	5,834,422	Sep 28, 2013
COMBIVENT RESPIMAT	Boehringer Ingelheim	albuterol sulfate; ipratropium bromide	5,911,851	Sep 29, 2013
COMBIVENT RESPIMAT	Boehringer Ingelheim	albuterol sulfate; ipratropium bromide	6,503,362	Sep 29, 2013
COMBIVENT RESPIMAT	Boehringer Ingelheim	albuterol sulfate; ipratropium bromide	6,007,676	Sep 29, 2013
COMBIVENT RESPIMAT	Boehringer Ingelheim	albuterol sulfate; ipratropium bromide	5,472,143	Sep 29, 2013
LIDOSITE TOPICAL SYSTEM KIT	Vyteris	epinephrine; lidocaine hydrochloride	5,873,850	Sep 30, 2013
LEVULAN	Dusa	aminolevulinic acid hydrochloride	5,079,262	Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KIT	Vyteris	epinephrine; lidocaine hydrochloride	6,385,488	Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KIT	Vyteris	epinephrine; lidocaine hydrochloride	6,377,847	Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KIT	Vyteris	epinephrine; lidocaine hydrochloride	5,246,418	Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KIT	Vyteris	epinephrine; lidocaine hydrochloride	6,862,473	Sep 30, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

Clinical trial information
International patent families
International patent priority and PCT information
Patent maintenance
Full-text patent downloads
Sales data (top 200 drugs)
Paragraph IV challenges
Tentative approvals
Dynamic search capabilities with data export
More…

See the Database Preview and Plan Comparison.
Contact Us with any questions.

1 Likes

/1 Tweets/in General Biotechnology

September 9, 2013

09 Sep 2013

Apply Now for the AUTM 2014 Venture Forum

I will be helping judge the AUTM Venture Forum again this year. The competition features a $10,000 prize for the first-place startup company, and valuable guidance and exposure for all entrants.